深圳市宇健生物医药

Shenzhen Yujian Biomedical is a biotechnology company focused on the discovery and development of innovative drugs using targeted protein degradation (TPD) technology. The company utilizes its proprietary D3 (Degradation-based Drug Discovery) platform to develop Proteolysis-Targeting Chimeras (PROTACs) and molecular glues for the treatment of cancer and autoimmune diseases. By targeting proteins previously considered undruggable, Yujian Biomedical aims to address significant unmet medical needs in precision oncology and immunology. The firm is headquartered in Shenzhen, China, and was founded in 2021 by Dr. Li Yujian, an expert in medicinal chemistry and protein degradation. The company has received significant backing from prominent regional investors, including Shenzhen Capital Group and the Shenzhen Angel FOF.